Uncovering the Elusive Nature of B Lymphocytes and Immunoglobulin in the Central Nervous System during Alzheimer’s Disease 2302553

Abstract Introduction Alzheimer’s Disease (AD) is a fatal, incurable neurodegenerative disease defined by amyloid-beta plaques, tau neurofibrillary tangles, chronic neuroinflammation, and elevated cognitive deficiency. Dysregulation of the Neuro-Immune axis, an immune cell network tasked with protecting the central nervous system (CNS), has been correlated to blood-brain-barrier dysfunction in early AD. This results in harmful inflammatory responses such as lymphocyte activation and autoantibody production; however, these CNS antibody-secreting cells are not properly defined. Genetic deletion of whole lymphocytes in AD murine models showed increased amyloid pathology and neuroinflammation, yet targeted B cell depletion resulted in less plaque burden and halting of memory defects. In addition, there is evidence of immunoglobulin deposition in the AD mice parenchyma. Thus, it is unclear if these lymphocytes are pathogenic or protective in AD, and what binding targets are driving antibody localization to the brain. Methods Using cerebrospinal fluid (CSF) samples from a clinical cohort of AD patients, we will characterize the CNS B lymphocyte and immunoglobulin compartment through three aims: (1) quantification of antibody titres and neuroinflammatory biomarkers (ELISA), (2) investigation of single-cell transcriptional differences and clonality (scRNAseq), and (3) identification of self-antigen targets via human proteomic assays (Microarray, PhIPseq). Results We predict AD CSF will have elevated levels of class-switched antibodies, inflammatory cytokines, and neuronal damage biomarkers. Single-cell sequencing will show that AD-derived B cells experience transcriptional reprogramming associated with increased activation, antibody production, and clonal expansion. Lastly, the proteomic assays will yield several antibody hits of targeted antigens consisting of human proteins present in the CNS niche. Conclusion Completing these specific aims will allow for a clearer understanding of the B cell and antibody response in AD. Funding Source NIH - Intramural Research Program (IRP) Topic Categories Neuroimmunology (NEUR)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2026-07-28
DOI
https://doi.org/10.1093/jimmun/vkag141.1247
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Uncovering the Elusive Nature of B Lymphocytes and Immunoglobulin in the Central Nervous System during Alzheimer’s Disease 2302553

Robert Maul, Patricia Gearhart, Braxton Greer, Angel Delgado
The Journal of Immunology
Alzheimer's disease research and treatments
article

Uncovering the Elusive Nature of B Lymphocytes and Immunoglobulin in the Central Nervous System during Alzheimer’s Disease 2302553

Robert Maul, Patricia Gearhart, Braxton Greer, Angel Delgado
article en

Abstract

Abstract Introduction Alzheimer’s Disease (AD) is a fatal, incurable neurodegenerative disease defined by amyloid-beta plaques, tau neurofibrillary tangles, chronic neuroinflammation, and elevated cognitive deficiency. Dysregulation of the Neuro-Immune axis, an immune cell network tasked with protecting the central nervous system (CNS), has been correlated to blood-brain-barrier dysfunction in early AD. This results in harmful inflammatory responses such as lymphocyte activation and autoantibody production; however, these CNS antibody-secreting cells are not properly defined. Genetic deletion of whole lymphocytes in AD murine models showed increased amyloid pathology and neuroinflammation, yet targeted B cell depletion resulted in less plaque burden and halting of memory defects. In addition, there is evidence of immunoglobulin deposition in the AD mice parenchyma. Thus, it is unclear if these lymphocytes are pathogenic or protective in AD, and what binding targets are driving antibody localization to the brain. Methods Using cerebrospinal fluid (CSF) samples from a clinical cohort of AD patients, we will characterize the CNS B lymphocyte and immunoglobulin compartment through three aims: (1) quantification of antibody titres and neuroinflammatory biomarkers (ELISA), (2) investigation of single-cell transcriptional differences and clonality (scRNAseq), and (3) identification of self-antigen targets via human proteomic assays (Microarray, PhIPseq). Results We predict AD CSF will have elevated levels of class-switched antibodies, inflammatory cytokines, and neuronal damage biomarkers. Single-cell sequencing will show that AD-derived B cells experience transcriptional reprogramming associated with increased activation, antibody production, and clonal expansion. Lastly, the proteomic assays will yield several antibody hits of targeted antigens consisting of human proteins present in the CNS niche. Conclusion Completing these specific aims will allow for a clearer understanding of the B cell and antibody response in AD. Funding Source NIH - Intramural Research Program (IRP) Topic Categories Neuroimmunology (NEUR)

The Journal of ImmunologyVol. 215(Supplement_1)
National Institutes of Health (US), Institute on Aging (US), National Institute on Aging (US)
Good health and well-being
Openalex Percentile: Top 9%
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.